Lewis C Cantley

List of Publications by Year
in descending order

525 papers	161,452 citations	43 180 h-index	42 386 g-index
724 all docs	724 docs citations	724 times ranked	114080 citing authors

#	Article	IF	Citations
1	NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis. Journal of Cell Biology, 2024, 223, .	5.1	1
2	Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. Nature Cancer, 2024, 5, 433-447.	12.0	4
3	The intrinsic substrate specificity of the human tyrosine kinome. Nature, 2024, 629, 1174-1181.	35.3	3
4	Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science, 2024, 384, .	19.6	3
5	Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 2023, 29, 1125-1136.	7.1	9
6	An atlas of substrate specificities for the human serine/threonine kinome. Nature, 2023, 613, 759-766.	35.3	221
7	LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discovery, 2023, 13, 1002-1025.	14.0	10
8	Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2. Science Translational Medicine, 2023, 15, .	13.2	20
9	Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor. Nature Chemical Biology, 2023, 19, 815-824.	7.8	21
10	RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Nature, 2023, 617, 147-153.	35.3	36
11	The Hallmarks of a Cancer Discovery. Cancer Discovery, 2023, 13, 797-798.	14.0	3
12	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nature Reviews Clinical Oncology, 2022, 19, 114-131.	27.1	96
13	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 1493-1499.	7.1	29
14	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. ELife, 2022, 11, .	5.8	43
15	Altered propionate metabolism contributes to tumour progression and aggressiveness. Nature Metabolism, 2022, 4, 435-443.	11.1	44
16	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports, 2022, 40, 100974.	0.7	8
17	At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nature Reviews Clinical Oncology, 2022, 19, 471-485.	27.1	74
18	Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma. Cancer Research, 2022, 82, 2403-2416.	0.9	12

#	Article	IF	Citations
19	Developing dietary interventions as therapy for cancer. Nature Reviews Cancer, 2022, 22, 452-466.	28.2	70
20	Discovery and Characterization of a Novel Allosteric Small-Molecule Inhibitor of NADP⁺-Dependent Malic Enzyme 1. Biochemistry, 2022, 61, 1548-1553.	2.6	6
21	PI3K drives the de novo synthesis of coenzyme A from vitamin B5. Nature, 2022, 608, 192-198.	35.3	42
22	Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. Nature Communications, 2022, 13, .	12.8	30
23	Tumor-produced and aging-associated oncometabolite methylmalonic acid promotes cancer-associated fibroblast activation to drive metastatic progression. Nature Communications, 2022, 13, .	12.8	23
24	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discovery, 2022, 12, 2475-2481.	14.0	0
25	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Research, 2022, 82, 3861-3867.	0.9	0
26	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Molecular Cancer Research, 2022, 20, 1591-1597.	3.4	0
27	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1995-2001.	1.9	0
28	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Immunology Research, 2022, 10, 1282-1288.	3.2	0
29	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Molecular Cancer Therapeutics, 2022, 21, 1625-1631.	3.7	1
30	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prevention Research, 2022, 15, 705-712.	1.5	0
31	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Blood Cancer Discovery, 2022, 3, 469-475.	5.7	0
32	High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells. Cell Metabolism, 2021, 33, 145-159.e6.	15.5	40
33	Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature, 2021, 589, 270-275.	35.3	420
34	A Decade of Cancer Discovery. Cancer Discovery, 2021, 11, 795-797.	14.0	2
35	GLUT5 (SLC2A5) enables fructose-mediated proliferation independent of ketohexokinase. Cancer & Metabolism, 2021, 9, 12.	5.1	12
36	DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Neuro-Oncology Advances, 2021, 3, i7-i8.	0.7	0

#	Article	IF	Citations
37	FSMP-10. CYSTEINE INDUCES CYTOTOXICITY IN GLIOBLASTOMA THROUGH MITOCHONDRIAL HYDROGEN PEROXIDE PRODUCTION. Neuro-Oncology Advances, 2021, 3, i18-i18.	0.7	0
38	Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer, 2021, 2, 414-428.	12.0	176
39	Dietary fructose improves intestinal cell survival and nutrient absorption. Nature, 2021, 597, 263-267.	35.3	157
40	Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nature Communications, 2021, 12, 640.	12.8	24
41	Distribution and localization of phosphatidylinositol 5â€phosphate, 4â€kinase alpha and beta in the brain. Journal of Comparative Neurology, 2021, 529, 434-449.	1.9	6
42	EXTH-12. INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND PLATELET-DERIVED GROWTH FACTOR RECEPTOR-ALPHA EXERTS SYNERGISTIC EFFICACY IN GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi165-vi166.	1.2	0
43	FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma. Blood, 2021, 138, 30-30.	1.4	0
44	Phase II, 2â€stage, 2â€arm, PIK3CA mutation stratified trial of MKâ€2206 in recurrent endometrial cancer. International Journal of Cancer, 2020, 147, 413-422.	5.3	40
45	Structureâ€“Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 346-352.	3.0	14
46	A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth. Biochemical and Biophysical Research Communications, 2020, 522, 633-638.	2.2	38
47	Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes and Development, 2020, 34, 1452-1473.	5.8	55
48	A â€˜fastâ€™er way to treat breast cancer. Nature Metabolism, 2020, 2, 559-560.	11.1	1
49	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.1	72
50	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications, 2020, 11, 5488.	12.8	29
51	Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature, 2020, 585, 283-287.	35.3	139
52	Phosphorylation-dependent substrate selectivity of protein kinase B (AKT1). Journal of Biological Chemistry, 2020, 295, 8120-8134.	3.4	38
53	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	14.0	169
54	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. Cancer Discovery, 2020, 10, 1226-1239.	14.0	36

#	Article	IF	Citations
55	Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Frontiers in Chemistry, 2020, 8, 147.	3.6	14
56	Insulinâ€“PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nature Reviews Endocrinology, 2020, 16, 276-283.	9.4	177
57	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT) Tj ETQq1 1 0.784314 rgBT /Overlock	3.3	
58	Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology, 2020, 27, 525-537.e6.	5.0	40
59	Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer & Metabolism, 2020, 8, 1.	5.1	37
60	Discovery and Structureâ€“Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 4880-4895.	6.5	19
61	TAMI-38. CYSTEINE-PROMOTING COMPOUNDS INDUCE MITOCHONDRIAL TOXICITY IN GLIOBLASTOMA THROUGH ALTERED PYRUVATE AND SERINE METABOLISM. Neuro-Oncology, 2020, 22, ii221-ii221.	1.2	0
62	Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2503-2510.	2.3	41
63	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	19.6	212
64	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell, 2019, 36, 402-417.e13.	16.4	76
65	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.3	33
66	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell, 2019, 35, 916-931.e9.	16.4	81
67	PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism. Cell Reports, 2019, 27, 1991-2001.e5.	6.2	41
68	Dietary Fat and Sugar in Promoting Cancer Development and Progression. Annual Review of Cancer Biology, 2019, 3, 255-273.	4.2	29
69	Regulation of folate and methionine metabolism by multisite phosphorylation of human methylenetetrahydrofolate reductase. Scientific Reports, 2019, 9, 4190.	3.4	27
70	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.6	205
71	Targeting cancer vulnerabilities with high-dose vitamin C. Nature Reviews Cancer, 2019, 19, 271-282.	28.2	264
72	Mapping Post-Translational Modifications of de Novo Purine Biosynthetic Enzymes: Implications for Pathway Regulation. Journal of Proteome Research, 2019, 18, 2078-2087.	3.7	15

#	Article	IF	Citations
73	Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chemical Biology, 2019, 26, 804-817.e12.	5.0	23
74	Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance. Journal of Lipid Research, 2019, 60, 747-752.	4.1	16
75	EXTH-36. PI3K INHIBITION IN CONJUNCTION WITH THE KETOGENIC DIET REDUCES GROWTH AND NEUROINFLAMMATION IN PEDIATRIC HIGH-GRADE GLIOMA. Neuro-Oncology, 2019, 21, vi89-vi90.	1.2	2
76	Quantitative InÂVivo Proteomics of Metformin Response in Liver Reveals AMPK-Dependent and -Independent Signaling Networks. Cell Reports, 2019, 29, 3331-3348.e7.	6.2	34
77	Human primary immunodeficiency caused by expression of a kinase-dead p110Î´ mutant. Journal of Allergy and Clinical Immunology, 2019, 143, 797-799.e2.	2.8	34
78	Toward a better understanding of folate metabolism in health and disease. Journal of Experimental Medicine, 2019, 216, 253-266.	8.6	131
79	Rac-Mediated Macropinocytosis of Extracellular Protein Promotes Glucose Independence in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 37.	3.8	47
80	A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification. Journal of the American Chemical Society, 2019, 141, 191-203.	14.1	69
81	Chromosomal instability drives metastasis through a cytosolic DNA response. Nature, 2018, 553, 467-472.	35.3	1,084
82	PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3KÎ± Inhibitors. Clinical Cancer Research, 2018, 24, 1426-1435.	7.1	28
83	Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E743-E752.	7.4	97
84	Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Molecular Cell, 2018, 70, 531-544.e9.	9.4	76
85	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discovery, 2018, 8, 354-369.	14.0	65
86	Mitochondrial One-Carbon Pathway Supports Cytosolic Folate Integrity in Cancer Cells. Cell, 2018, 175, 1546-1560.e17.	27.3	92
87	Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. New England Journal of Medicine, 2018, 379, 2052-2062.	29.6	233
88	The chromatin remodeler RSF1 controls centromeric histone modifications to coordinate chromosome segregation. Nature Communications, 2018, 9, 3848.	12.8	20
89	Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry, 2018, 57, 6604-6614.	2.6	30
90	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	11.1	32

#	Article	IF	Citations
91	The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment. Cell, 2018, 174, 1347-1360.	27.3	461
92	Cancer metabolism gets physical. Science Translational Medicine, 2018, 10, .	13.2	38
93	A Glycolysis Outsider Steps into the Cancer Spotlight. Cell Metabolism, 2018, 28, 3-4.	15.5	34
94	Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2675-2678.	2.3	29
95	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature, 2018, 560, 499-503.	35.3	523
96	A Topical Report on the Design Principles of Metabolism. , 2018, , 29-44.		0
97	Obesity, Insulin Resistance and Cancer: The PI3K connection. FASEB Journal, 2018, 32, 250.4.	0.4	0
98	Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies. Blood, 2018, 132, 213-213.	1.4	1
99	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.1	277
100	Death-associated protein kinase 1 phosphorylates NDRG2 and induces neuronal cell death. Cell Death and Differentiation, 2017, 24, 238-250.	11.1	49
101	Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. Journal of Investigative Dermatology, 2017, 137, 1135-1143.	0.7	23
102	Î±-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH). Journal of Medicinal Chemistry, 2017, 60, 1591-1597.	6.5	56
103	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 2017, 7, 750-765.	14.0	115
104	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1255-1262.	2.6	19
105	PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discovery, 2017, 7, 380-390.	14.0	101
106	Membrane Lipids Speak to Histones. Molecular Cell, 2017, 66, 163-164.	9.4	1
107	PI3K-p110Î± mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85Î±. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7095-7100.	7.4	79
108	Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to Insulin. Cell Reports, 2017, 19, 2005-2013.	6.2	186

#	Article	IF	Citations
109	Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477.	14.0	769
110	PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Molecular Cell, 2017, 65, 999-1013.e7.	9.4	108
111	Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation. Cell Reports, 2017, 20, 721-736.	6.2	42
112	The PI3K Pathway in Human Disease. Cell, 2017, 170, 605-635.	27.3	1,849
113	Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling. Cell, 2017, 171, 1545-1558.e18.	27.3	169
114	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 2017, 32, 71-87.e7.	16.4	403
115	SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls. Blood, 2017, 130, 643-643.	1.4	9
116	Obesity and Cancer Mechanisms: Cancer Metabolism. Journal of Clinical Oncology, 2016, 34, 4277-4283.	5.7	253
117	A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase. Molecular and Cellular Oncology, 2016, 3, e1164280.	0.7	22
118	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nature Cell Biology, 2016, 18, 572-578.	9.9	205
119	Seeking out the sweet spot in cancer therapeutics: an interview with Lewis Cantley. DMM Disease Models and Mechanisms, 2016, 9, 911-916.	2.4	0
120	Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature, 2016, 536, 479-483.	35.3	880
121	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Recent Results in Cancer Research, 2016, 207, 39-72.	0.0	154
122	Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9810-9815.	7.4	67
123	Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4338-47.	7.4	78
124	A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2. Scientific Reports, 2016, 6, 20471.	3.4	37
125	Deletion of the gene Pip4k2c , a novel phosphatidylinositol kinase, results in hyperactivation of the immune system. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7596-7601.	7.4	51
126	PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics. Cancer Drug Discovery and Development, 2016, , 1-25.	0.0	0

#	Article	IF	Citations
127	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. Cell, 2016, 164, 433-446.	27.3	321
128	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	4.7	13
129	Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1778-1783.	7.4	250
130	The Phosphatidylinositol 3â€Kinase Pathway in Human Malignancies. , 2015, , 315-324.		0
131	Acetate Fuels the Cancer Engine. Cell, 2015, 160, 567.	27.3	1
132	Regulation of mTORC1 by PI3K signaling. Trends in Cell Biology, 2015, 25, 545-555.	8.0	682
133	Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2056-2065.	3.7	77
134	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015, 21, 457-466.	29.5	232
135	AACR Cancer Progress Report 2015. Clinical Cancer Research, 2015, 21, S1-S128.	7.1	38
136	NRF2 regulates serine biosynthesis in nonâ€“small cell lung cancer. Nature Genetics, 2015, 47, 1475-1481.	20.1	606
137	Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ÃŸ-lapachone. Cancer & Metabolism, 2015, 3, 12.	5.1	110
138	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, 2015, 5, 1296-1313.	14.0	152
139	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discovery, 2015, 5, 1194-1209.	14.0	310
140	Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy. Cellular Signalling, 2015, 27, 2389-2400.	3.6	10
141	Cancerâ€™s Fuel Choice: New Flavors for a Picky Eater. Molecular Cell, 2015, 60, 514-523.	9.4	128
142	EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. Nature Structural and Molecular Biology, 2015, 22, 983-990.	7.8	38
143	Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the Brain. Cancer Research, 2015, 75, 554-565.	0.9	140
144	Computational Prediction of Protein-Protein Interactions. Methods in Molecular Biology, 2015, 1278, 57-75.	0.7	37

#	Article	IF	Citations
145	Diverting Glycolysis to Combat Oxidative Stress. , 2015, , 3-23.		95
146	Idelalisib â€" A PI3KÎ´ Inhibitor for B-Cell Cancers. New England Journal of Medicine, 2014, 370, 1061-1062.	29.6	86
147	Acetate Fuels the Cancer Engine. Cell, 2014, 159, 1492-1494.	27.3	81
148	A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition. Cancer Research, 2014, 74, 15-23.	0.9	57
149	Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome. Cell, 2014, 156, 771-785.	27.3	642
150	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature, 2014, 508, 541-545.	35.3	297
151	BRD7, a Tumor Suppressor, Interacts with p85Î± and Regulates PI3K Activity. Molecular Cell, 2014, 54, 193-202.	9.4	79
152	Signal Transduction: From the Atomic Age to the Post-Genomic Era. Cold Spring Harbor Perspectives in Biology, 2014, 6, a022913-a022913.	5.2	24
153	Targeting Metabolic Scavenging in Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 6-8.	7.1	9
154	Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis. Cell, 2014, 158, 1309-1323.	27.3	309
155	A Fundamental Trade-off in Covalent Switching and Its Circumvention by Enzyme Bifunctionality in Glucose Homeostasis. Journal of Biological Chemistry, 2014, 289, 13010-13025.	3.4	33
156	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1202-1209.	5.7	163
157	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 2014, 514, 628-632.	35.3	1,046
158	BRD7 Regulates XBP1sâ€™ Activity and Glucose Homeostasis through Its Interaction with the Regulatory Subunits of PI3K. Cell Metabolism, 2014, 20, 73-84.	15.5	57
159	Vulnerabilities of PTENâ€"TP53-Deficient Prostate Cancers to Compound PARPâ€"PI3K Inhibition. Cancer Discovery, 2014, 4, 896-904.	14.0	88
160	FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO Journal, 2013, 32, 2589-2602.	7.6	136
161	F stands for fructose and fat. Nature, 2013, 502, 181-182.	35.3	54
162	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. Cell, 2013, 155, 397-409.	27.3	446

#	Article	IF	Citations
163	Lin28 Enhances Tissue Repair by Reprogramming Cellular Metabolism. Cell, 2013, 155, 778-792.	27.3	333
164	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. Cell, 2013, 155, 844-857.	27.3	182
165	What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway. Cancer Discovery, 2013, 3, 1345-1354.	14.0	135
166	Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. Cancer Research, 2013, 73, 4429-4438.	0.9	180
167	Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation. Molecular Cell, 2013, 52, 161-172.	9.4	120
168	Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nature Structural and Molecular Biology, 2013, 20, 46-52.	7.8	83
169	Metabolic Stress Controls mTORC1 Lysosomal Localization and Dimerization by Regulating the TTT-RUVBL1/2 Complex. Molecular Cell, 2013, 49, 172-185.	9.4	185
170	Cancer metabolism: fatty acid oxidation in the limelight. Nature Reviews Cancer, 2013, 13, 227-232.	28.2	1,016
171	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 2013, 496, 101-105.	35.3	1,606
172	AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1. Molecular Cell, 2013, 49, 1167-1175.	9.4	537
173	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine, 2013, 19, 619-625.	29.5	855
174	Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nature Biotechnology, 2013, 31, 522-529.	20.4	391
175	Stem cell metabolism in tissue development and aging. Development (Cambridge), 2013, 140, 2535-2547.	2.5	488
176	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	20.1	139
177	MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 2013, 154, 311-324.	27.3	420
178	The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4. Cell, 2013, 153, 840-854.	27.3	523
179	Fetal Deficiency of Lin28 Programs Life-Long Aberrations in Growth and Glucose Metabolism. Stem Cells, 2013, 31, 1563-1573.	3.5	114
180	Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle, 2013, 12, 1987-1988.	2.7	70

#	Article	IF	Citations
181	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	14.0	132
182	Phosphoinositides and membrane curvature switch the mode of actin polymerization via selective recruitment of toca-1 and Snx9. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7193-7198.	7.4	56
183	Protein Tyrosine Phosphatase 1B Regulates Pyruvate Kinase M2 Tyrosine Phosphorylation. Journal of Biological Chemistry, 2013, 288, 17360-17371.	3.4	47
184	Phenformin enhances the therapeutic benefit of BRAF ^{V600E} inhibition in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18226-18231.	7.4	204
185	Identification of CDCP1 as a hypoxia-inducible factor 2Î± (HIF-2Î±) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3483-3488.	7.4	58
186	Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Science Signaling, 2013, 6, ra40.	5.1	21
187	A Homogeneous, High-Throughput Assay for Phosphatidylinositol 5-Phosphate 4-Kinase with a Novel, Rapid Substrate Preparation. PLoS ONE, 2013, 8, e54127.	2.5	43
188	Ras Activity Regulation by Monoubiquitination. FASEB Journal, 2013, 27, 1046.3.	0.4	0
189	Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling. Circulation, 2012, 126, 2208-2219.	6.2	92
190	ÍºB Kinase Î± Phosphorylation of TRAF4 Downregulates Innate Immune Signaling. Molecular and Cellular Biology, 2012, 32, 2479-2489.	2.4	30
191	Cancer Discovery at One Year: The Editors' Interim Analysis. Cancer Discovery, 2012, 2, vi-vi.	14.0	0
192	Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. Molecular and Cellular Proteomics, 2012, 11, M111.014688.	3.9	93
193	AACR Cancer Progress Report 2012. Clinical Cancer Research, 2012, 18, S1-S100.	7.1	28
194	Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. Journal of Molecular Cell Biology, 2012, 4, 79-87.	3.3	86
195	ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biology, 2012, 14, 1295-1304.	9.9	731
196	SIRT6 Puts Cancer Metabolism in the Driverâ€™s Seat. Cell, 2012, 151, 1155-1156.	27.3	28
197	Small Molecule Activation of PKM2 in Cancer Cells Induces Serine Auxotrophy. Chemistry and Biology, 2012, 19, 1187-1198.	6.2	154
198	Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology, 2012, 8, 839-847.	7.8	642

#	Article	IF	Citations
199	p85Î± SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation. Molecular Cell, 2012, 45, 719-730.	9.4	65
200	Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State. Cell, 2012, 149, 49-62.	27.3	349
201	p70S6 Kinase Phosphorylates AMPK on Serine 491 to Mediate Leptin's Effect on Food Intake. Cell Metabolism, 2012, 16, 104-112.	15.5	243
202	Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. BMC Proceedings, 2012, 6, .	1.0	2
203	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. Cancer Discovery, 2012, 2, 1048-1063.	14.0	397
204	Development of a High-Throughput Assay for Identifying Inhibitors of TBK1 and IKKÎµ. PLoS ONE, 2012, 7, e41494.	2.5	34
205	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483, 613-617.	35.3	432
206	Sugar free, cancer free?. Nutrition, 2012, 28, 1036.	2.6	5
207	Breathless cancer cells get fat on glutamine. Cell Research, 2012, 22, 443-446.	12.0	56
208	Ancient Sensor for Ancient Drug. Science, 2012, 336, 813-814.	19.6	15
209	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell, 2012, 149, 656-670.	27.3	1,641
210	Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogenâ€activated protein Kinase (MAPK) and Phosphatidylinositolâ€3â€kinase (PI3K)/AKT pathways. Journal of Cellular Physiology, 2012, 227, 1709-1720.	4.1	139
211	Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS ONE, 2012, 7, e49466.	2.5	53
212	Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice. F1000 Biology Reports, 2012, 4, 2.	4.0	28
213	Cancer Cell Metabolism. , 2012, , 245-261.		0
214	Human pluripotent stem cells decouple respiration from energy production. EMBO Journal, 2011, 30, 4851-4852.	7.6	36
215	Metabolic Regulation of Protein N-Alpha-Acetylation by Bcl-xL Promotes Cell Survival. Cell, 2011, 146, 607-620.	27.3	188
216	Metabolic Flux and the Regulation of Mammalian Cell Growth. Cell Metabolism, 2011, 14, 443-451.	15.5	386

#	Article	IF	Citations
217	Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size. Molecular Cell, 2011, 42, 50-61.	9.4	232
218	mTOR Drives Its Own Activation via SCFÎ²TrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR. Molecular Cell, 2011, 44, 290-303.	9.4	226
219	Chemical Genetic Screen for AMPKÎ±2 Substrates Uncovers a Network of Proteins Involved in Mitosis. Molecular Cell, 2011, 44, 878-892.	9.4	238
220	PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell and Melanoma Research, 2011, 24, 1112-1115.	3.3	121
221	Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations. Open Biology, 2011, 1, 110012.	3.7	92
222	TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. Biochemical Journal, 2011, 437, 157-167.	3.7	56
223	Cell-to-Cell Variability in PI3K Protein Level Regulates PI3K-AKT Pathway Activity in Cell Populations. Current Biology, 2011, 21, 173-183.	3.9	92
224	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6322-6327.	2.3	55
225	A Fluorescent Reporter of AMPK Activity and Cellular Energy Stress. Cell Metabolism, 2011, 13, 476-486.	15.5	136
226	Proteomic Screening Method for Phosphopeptide Motif Binding Proteins Using Peptide Libraries. Journal of Proteome Research, 2011, 10, 4158-4164.	3.7	14
227	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics, 2011, 43, 869-874.	20.1	972
228	Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85Î± Src homology-2 domains. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14157-14162.	7.4	71
229	The APL Paradigm and the â€œCo-Clinical Trialâ€•Project. Cancer Discovery, 2011, 1, 108-116.	14.0	119
230	Genetic selection for enhanced serine metabolism in cancer development. Cell Cycle, 2011, 10, 3812-3813.	2.7	33
231	Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors. Science Signaling, 2011, 4, ra13.	5.1	155
232	Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer. Cancer Research, 2011, 71, 5965-5975.	0.9	15
233	The Era of Cancer Discovery. Cancer Discovery, 2011, 1, 1-1.	14.0	37
234	High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discovery, 2011, 1, 170-185.	14.0	431

#	Article	IF	Citations
235	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	14.0	93
236	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation, 2011, 121, 4311-4321.	6.5	180
237	Development of an intracellularly acting inhibitory peptide selective for PKN. Biochemical Journal, 2010, 425, 445-543.	3.7	23
238	Evaluation of Substituted N,Nâ€²-Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase. Journal of Medicinal Chemistry, 2010, 53, 1048-1055.	6.5	137
239	Identification of small molecule inhibitors of pyruvate kinase M2. Biochemical Pharmacology, 2010, 79, 1118-1124.	4.5	210
240	Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3387-3393.	2.3	115
241	Altered metabolism in cancer. BMC Biology, 2010, 8, 88.	3.8	146
242	Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin. PLoS ONE, 2010, 5, e10504.	2.5	91
243	Targeting a Common Collaborator in Cancer Development. Science Translational Medicine, 2010, 2, 48ps45.	13.2	29
244	Rewiring of glycolysis in cancer cell metabolism. Cell Cycle, 2010, 9, 4253-4253.	2.7	31
245	The Phosphoinositide 3-Kinase Regulatory Subunit p85Î± Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. Cancer Research, 2010, 70, 5305-5315.	0.9	145
246	The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1894-1899.	7.4	366
247	PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15145-15150.	7.4	206
248	Chemoprevention Meets Glucose Control. Cancer Prevention Research, 2010, 3, 1049-1052.	1.5	55
249	Characterization of PXK as a Protein Involved in Epidermal Growth Factor Receptor Trafficking. Molecular and Cellular Biology, 2010, 30, 1689-1702.	2.4	26
250	Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent Balancing of Metabolic Demand with Supply. Molecular Cell, 2010, 38, 487-499.	9.4	238
251	Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetics and Development, 2010, 20, 87-90.	3.3	506
252	Class IA Phosphatidylinositol 3-Kinase in Pancreatic Î² Cells Controls Insulin Secretion by Multiple Mechanisms. Cell Metabolism, 2010, 12, 619-632.	15.5	104

#	Article	IF	Citations
253	Aktâ€“RSKâ€“S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Science Signaling, 2010, 3, ra64.	5.1	265
254	Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells. Science, 2010, 329, 1492-1499.	19.6	592
255	Getting Knit-PI3Ky: PIK3CA Mutation Status to Direct Multimodality Therapy?. Clinical Cancer Research, 2009, 15, 6748-6750.	7.1	2
256	The antiproliferative cytostatic effects of a self-activating viridin prodrug. Molecular Cancer Therapeutics, 2009, 8, 1666-1675.	3.7	19
257	‹i›PIK3CA‹/i› Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer. Journal of Clinical Oncology, 2009, 27, 1477-1484.	5.7	307
258	Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis. Endocrinology, 2009, 150, 4874-4882.	2.8	83
259	Lewis C. Cantley. Current Biology, 2009, 19, R540-R541.	3.9	1
260	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. Cancer Cell, 2009, 16, 115-125.	16.4	422
261	Organâ€specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from geneâ€targeting of the PI3K regulatory isoforms p85Î±, p55Î±, and p50Î±. Developmental Dynamics, 2009, 238, 2670-2679.	1.9	55
262	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 462, 739-744.	35.3	3,427
263	Cancer's insatiable appetite. Nature Biotechnology, 2009, 27, 916-917.	20.4	44
264	Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 2009, 324, 1029-1033.	19.6	12,686
265	A Wortmanninâ^'Cetuximab as a Double Drug. Bioconjugate Chemistry, 2009, 20, 2185-2189.	3.7	8
266	Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy. Cell, 2009, 136, 521-534.	27.3	1,516
267	Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation. Molecular Cell, 2009, 33, 237-247.	9.4	324
268	Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKÉ› Promotes Cell Transformation. Molecular Cell, 2009, 34, 461-472.	9.4	207
269	Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth. Science Signaling, 2009, 2, ra73.	5.1	654
270	Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochemical Journal, 2009, 424, 47-60.	3.7	188

#	Article	IF	Citations
271	A labelâ€free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics, 2008, 8, 994-999.	3.0	215
272	Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 2008, 452, 181-186.	35.3	904
273	The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008, 452, 230-233.	35.3	2,491
274	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine, 2008, 14, 1351-1356.	29.5	1,253
275	A Sweet New Role for EGFR in Cancer. Cancer Cell, 2008, 13, 375-376.	16.4	42
276	PI3K Enters Beta-Testing. Cell Metabolism, 2008, 8, 179-181.	15.5	7
277	Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. Journal of Clinical Investigation, 2008, 118, 1796-1805.	6.5	297
278	Fate of a Bioactive Fluorescent Wortmannin Derivative in Cells. Bioconjugate Chemistry, 2008, 19, 130-137.	3.7	16
279	Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9739-9744.	7.4	97
280	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation, 2008, 118, 3065-74.	6.5	1,140
281	Slow Self-Activation Enhances The Potency of Viridin Prodrugs. Journal of Medicinal Chemistry, 2008, 51, 4699-4707.	6.5	12
282	Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5680-5685.	7.4	70
283	Interpreting Sequences from Mastodon and T. rex. Science, 2007, 317, 1324-1325.	19.6	45
284	Î²B Kinase Î² Phosphorylates the K63 Deubiquitinase A20 To Cause Feedback Inhibition of the NF-Î²B Pathway. Molecular and Cellular Biology, 2007, 27, 7451-7461.	2.4	164
285	Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 819-822.	7.4	250
286	Coordinated Regulation of Toll-Like Receptor and NOD2 Signaling by K63-Linked Polyubiquitin Chains. Molecular and Cellular Biology, 2007, 27, 6012-6025.	2.4	164
287	Deletion of the phosphoinositide 3-kinase p110Â gene attenuates murine atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8077-8082.	7.4	104
288	AKT1 Overexpression in Endothelial Cells Leads to the Development of Cutaneous Vascular Malformations In Vivo. Archives of Dermatology, 2007, 143, 504-6.	1.4	57

#	Article	IF	Citations
289	T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood, 2007, 109, 2894-2902.	1.4	54
290	Protein Sequences from Mastodon and Tyrannosaurus Rex Revealed by Mass Spectrometry. Science, 2007, 316, 280-285.	19.6	274
291	AKT/PKB Signaling: Navigating Downstream. Cell, 2007, 129, 1261-1274.	27.3	5,361
292	Evolution of Ime2 Phosphorylation Sites on Cdk1 Substrates Provides a Mechanism to Limit the Effects of the Phosphatase Cdc14 in Meiosis. Molecular Cell, 2007, 25, 689-702.	9.4	72
293	PI3K Charges Ahead. Science, 2007, 317, 206-207.	19.6	43
294	The p85Î± Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance. Molecular and Cellular Biology, 2007, 27, 2830-2840.	2.4	75
295	D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology, 2007, 2, S396.	1.1	1
296	Covalent Reactions of Wortmannin under Physiological Conditions. Chemistry and Biology, 2007, 14, 321-328.	6.2	33
297	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 316, 1039-1043.	19.6	4,241
298	In-Gel Stable-Isotope Labeling (ISIL):â€‰ A Strategy for Mass Spectrometry-Based Relative Quantification. Journal of Proteome Research, 2006, 5, 155-163.	3.7	32
299	MMP-20 Is Predominately a Tooth-Specific Enzyme with a Deep Catalytic Pocket that Hydrolyzes Type V Collagenâ€. Biochemistry, 2006, 45, 3863-3874.	2.6	39
300	Wortmannin-C20 Conjugates Generate Wortmannin. Journal of Medicinal Chemistry, 2006, 49, 740-747.	6.5	20
301	Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metabolism, 2006, 3, 355-366.	15.5	100
302	Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCÎ»/Î¶. Cell Metabolism, 2006, 3, 343-353.	15.5	258
303	Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood, 2006, 107, 3868-3875.	1.4	183
304	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics, 2006, 7, 606-619.	16.4	2,899
305	Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441, 424-430.	35.3	1,855
306	PtdIns(5)P activates the host cell PI3-kinase/Akt pathway during Shigella flexneri infection. EMBO Journal, 2006, 25, 1024-1034.	7.6	212

#	Article	IF	Citations
307	Hem-1 Complexes Are Essential for Rac Activation, Actin Polymerization, and Myosin Regulation during Neutrophil Chemotaxis. PLoS Biology, 2006, 4, e38.	5.3	156
308	Phosphoinositide 3-kinase regulatory subunit p85Â suppresses insulin action via positive regulation of PTEN. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12093-12097.	7.4	150
309	Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16882-16887.	7.4	68
310	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation, 2006, 116, 2695-2706.	6.5	424
311	Modification of protein sub-nuclear localization by synthetic phosphoinositides: Evidence for nuclear phosphoinositide signaling mechanisms. Advances in Enzyme Regulation, 2005, 45, 171-185.	2.5	12
312	PtdIns(4,5)P2 Functions at the Cleavage Furrow during Cytokinesis. Current Biology, 2005, 15, 1407-1412.	3.9	173
313	Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in Mice. Molecular and Cellular Biology, 2005, 25, 1596-1607.	2.4	163
314	Increased P85Î± Is a Potent Negative Regulator of Skeletal Muscle Insulin Signaling and Induces in Vivo Insulin Resistance Associated with Growth Hormone Excess. Journal of Biological Chemistry, 2005, 280, 37489-37494.	3.4	124
315	Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy. Molecular and Cellular Biology, 2005, 25, 9491-9502.	2.4	189
316	The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. Journal of Cell Biology, 2005, 170, 455-464.	5.1	151
317	Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement. Molecular and Cellular Biology, 2005, 25, 2593-2606.	2.4	120
318	Diverse Biochemical Properties of Shp2 Mutants. Journal of Biological Chemistry, 2005, 280, 30984-30993.	3.4	260
319	The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes and Development, 2005, 19, 1692-1704.	5.8	339
320	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10238-10243.	7.4	43
321	Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8114-8119.	7.4	36
322	Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes and Development, 2005, 19, 1773-1778.	5.8	216
323	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3788-3793.	7.4	475
324	Differential Effects of Gefitinib and Cetuximab on Nonâ€“small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194.	6.2	296

#	Article	IF	Citations
325	DNA Damage-induced Association of ATM with Its Target Proteins Requires a Protein Interaction Domain in the N Terminus of ATM. Journal of Biological Chemistry, 2005, 280, 15158-15164.	3.4	62
326	Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase. Bioconjugate Chemistry, 2005, 16, 669-675.	3.7	17
327	The C2 Domain of PKCÎ´ Is a Phosphotyrosine Binding Domain. Cell, 2005, 121, 271-280.	27.3	226
328	Phosphatidyl Inositol (4,5)P2 Marks Megakaryocyte Internal Membranes and Is Associated with Megakaryocyte Maturation and Platelet Release.. Blood, 2005, 106, 732-732.	1.4	0
329	A Multi-enzyme Cascade of Hemoglobin Proteolysis in the Intestine of Blood-feeding Hookworms. Journal of Biological Chemistry, 2004, 279, 35950-35957.	3.4	157
330	A novel phosphatidylinositol(3,4,5)P3 pathway in fission yeast. Journal of Cell Biology, 2004, 166, 205-211.	5.1	80
331	Identification and Characterization of a Phosphoinositide Phosphate Kinase Homolog. Journal of Biological Chemistry, 2004, 279, 11672-11679.	3.4	23
332	Increased Insulin Sensitivity and Reduced Adiposity in Phosphatidylinositol 5-Phosphate 4-Kinase Î² â^'/â^' Mice. Molecular and Cellular Biology, 2004, 24, 5080-5087.	2.4	140
333	The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3329-3335.	7.4	1,582
334	Large-scale characterization of HeLa cell nuclear phosphoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12130-12135.	7.4	1,442
335	A rapid method for determining protein kinase phosphorylation specificity. Nature Methods, 2004, 1, 27-29.	19.2	344
336	The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Structural and Molecular Biology, 2004, 11, 60-66.	7.8	182
337	Identification of small molecule inhibitors of anthrax lethal factor. Nature Structural and Molecular Biology, 2004, 11, 67-72.	7.8	136
338	The Crohn's Disease Protein, NOD2, Requires RIP2 in Order to Induce Ubiquitinylation of a Novel Site on NEMO. Current Biology, 2004, 14, 2217-2227.	3.9	344
339	The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 2004, 6, 91-99.	16.4	973
340	Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells. Experimental Cell Research, 2004, 297, 224-234.	2.6	62
341	Using peptide libraries to identify optimal cleavage motifs for proteolytic enzymes. Methods, 2004, 32, 398-405.	3.8	21
342	Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. Current Biology, 2003, 13, 1259-1268.	3.9	1,061

#	Article	IF	Citations
343	Targeting the PI3K-Akt pathway in human cancer. Cancer Cell, 2003, 4, 257-262.	16.4	1,248
344	Rheb fills a GAP between TSC and TOR. Trends in Biochemical Sciences, 2003, 28, 573-576.	7.3	446
345	Peptide libraries: at the crossroads of proteomics and bioinformatics. Current Opinion in Chemical Biology, 2003, 7, 84-90.	6.2	51
346	The PHD Finger of the Chromatin-Associated Protein ING2 Functions as a Nuclear Phosphoinositide Receptor. Cell, 2003, 114, 99-111.	27.3	477
347	The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain. Cell, 2003, 115, 83-95.	27.3	699
348	Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Research, 2003, 31, 3635-3641.	13.8	1,470
349	Proteomic Screen Finds pSer/pThr-Binding Domain Localizing Plk1 to Mitotic Substrates. Science, 2003, 299, 1228-1231.	19.6	646
350	The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9867-9872.	7.4	151
351	Altered Signaling and Cell Cycle Regulation in Embryonal Stem Cells with a Disruption of the Gene for Phosphoinositide 3-Kinase Regulatory Subunit p85Î±. Journal of Biological Chemistry, 2003, 278, 5099-5108.	3.4	39
352	Positive and Negative Roles of p85Î± and p85Î² Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling. Journal of Biological Chemistry, 2003, 278, 48453-48466.	3.4	184
353	Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation. Journal of Cell Science, 2003, 116, 3611-3622.	2.0	169
354	Use of RNA Interference-mediated Gene Silencing and Adenoviral Overexpression to Elucidate the Roles of AKT/Protein Kinase B Isoforms in Insulin Actions. Journal of Biological Chemistry, 2003, 278, 28312-28323.	3.4	181
355	Binding Specificity and Regulation of the Serine Protease and PDZ Domains of HtrA2/Omi. Journal of Biological Chemistry, 2003, 278, 49417-49427.	3.4	120
356	Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13571-13576.	7.4	747
357	Peptide Substrate Specificities and Protein Cleavage Sites of Human Endometase/Matrilysin-2/Matrix Metalloproteinase-26. Journal of Biological Chemistry, 2002, 277, 35168-35175.	3.4	54
358	Increased insulin sensitivity in mice lacking p85Â subunit of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 419-424.	7.4	230
359	Interferon regulatory factor-3 is an in vivo target of DNA-PK. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2818-2823.	7.4	115
360	Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival. Molecular and Cellular Biology, 2002, 22, 965-977.	2.4	258

#	Article	IF	Citations
361	Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice. Molecular and Cellular Biology, 2002, 22, 2799-2809.	2.4	484
362	Phosphoinositide 3-kinase in immunological systems. Seminars in Immunology, 2002, 14, 7-18.	5.7	193
363	Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway. Molecular Cell, 2002, 10, 151-162.	9.4	1,389
364	Lipid Research Picks Up Speed on the Slopes of Taos. Developmental Cell, 2002, 2, 407-410.	6.9	3
365	Overview of the Alliance for Cellular Signaling. Nature, 2002, 420, 703-706.	35.3	134
366	A PtdInsP3- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nature Cell Biology, 2002, 4, 509-513.	9.9	482
367	An integrated vector system for cellular studies of phage display-derived peptides. Analytical Biochemistry, 2002, 308, 364-372.	2.4	8
368	Reduced expression of the murine p85Î± subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. Journal of Clinical Investigation, 2002, 109, 141-149.	6.5	193
369	Reduced expression of the murine p85Î± subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. Journal of Clinical Investigation, 2002, 109, 141-149.	6.5	126
370	The Peutz-Jegher Gene Product LKB1 Is a Mediator of p53-Dependent Cell Death. Molecular Cell, 2001, 7, 1307-1319.	9.4	297
371	A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nature Biotechnology, 2001, 19, 348-353.	20.4	513
372	Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnology, 2001, 19, 661-667.	20.4	533
373	In vivo near-infrared fluorescence imaging of osteoblastic activity. Nature Biotechnology, 2001, 19, 1148-1154.	20.4	373
374	The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nature Cell Biology, 2001, 3, 675-678.	9.9	574
375	Marked Differences between Metalloproteases Meprin A and B in Substrate and Peptide Bond Specificity. Journal of Biological Chemistry, 2001, 276, 13248-13255.	3.4	103
376	Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors. Journal of Biological Chemistry, 2001, 276, 22685-22698.	3.4	114
377	Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. Journal of Cell Biology, 2001, 155, 19-26.	5.1	483
378	Phosphatidylinositol 3-Kinase Confers Resistance to Encephalomyocarditis and Herpes Simplex Virus-Induced Cell Death Through the Activation of Distinct Downstream Effectors. Journal of Immunology, 2001, 167, 4553-4559.	0.8	27

#	Article	IF	Citations
379	TRANSCRIPTION: Translocating Tubby. Science, 2001, 292, 2019-2021.	19.6	23
380	Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. Journal of Clinical Investigation, 2001, 108, 1387-1395.	6.5	105
381	[12] Mapping specificity determinants for protein-protein association using protein fusions and random peptide libraries. Methods in Enzymology, 2000, 328, 157-170.	1.7	28
382	Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening. Nature Biotechnology, 2000, 18, 1080-1085.	20.4	55
383	Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85Î±. Nature Genetics, 2000, 26, 379-382.	20.1	278
384	Type IÎ± phosphatidylinositol-4-phosphate 5-kinase mediates Rac-dependent actin assembly. Current Biology, 2000, 10, 153-156.	3.9	234
385	The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO Journal, 2000, 19, 2537-2548.	7.6	543
386	TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO Journal, 2000, 19, 6778-6791.	7.6	635
387	Impaired Kit- but Not FcÎµRI-initiated Mast Cell Activation in the Absence of Phosphoinositide 3-Kinase p85Î± Gene Products. Journal of Biological Chemistry, 2000, 275, 6022-6029.	3.4	76
388	A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6687-6692.	7.4	39
389	Utilization of Oriented Peptide Libraries to Identify Substrate Motifs Selected by ATM. Journal of Biological Chemistry, 2000, 275, 22719-22727.	3.4	163
390	Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB. Journal of Biological Chemistry, 2000, 275, 36108-36115.	3.4	354
391	Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer. Journal of Biological Chemistry, 2000, 275, 19803-19807.	3.4	108
392	Biochemical Interactions Integrating Itk with the T Cell Receptor-initiated Signaling Cascade. Journal of Biological Chemistry, 2000, 275, 2219-2230.	3.4	246
393	A Peptide Library Approach Identifies a Specific Inhibitor for the ZAP-70 Protein Tyrosine Kinase. Molecular Cell, 2000, 6, 969-974.	9.4	29
394	The SH2 Domain-containing Inositol 5â€²-Phosphatase (SHIP) Recruits the p85 Subunit of Phosphoinositide 3-Kinase during FcÎ³RIIb1-mediated Inhibition of B Cell Receptor Signaling. Journal of Biological Chemistry, 1999, 274, 7489-7494.	3.4	53
395	SYK Is Upstream of Phosphoinositide 3-Kinase in B Cell Receptor Signaling. Journal of Biological Chemistry, 1999, 274, 32662-32666.	3.4	164
396	Grabbing phosphoproteins. Nature, 1999, 402, 30-31.	35.3	77

#	Article	IF	Citations
397	Pathways for phosphoinositide synthesis. Chemistry and Physics of Lipids, 1999, 98, 69-77.	3.3	78
398	The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function. Journal of Biological Chemistry, 1999, 274, 8347-8350.	3.4	900
399	Impaired B Cell Development and Proliferation in Absence of Phosphoinositide 3-Kinase p85Î±. Science, 1999, 283, 393-397.	19.6	612
400	New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4240-4245.	7.4	1,853
401	Crystal Structures of the XLP Protein SAP Reveal a Class of SH2 Domains with Extended, Phosphotyrosine-Independent Sequence Recognition. Molecular Cell, 1999, 4, 555-561.	9.4	240
402	Structural Analysis of 14-3-3 Phosphopeptide Complexes Identifies a Dual Role for the Nuclear Export Signal of 14-3-3 in Ligand Binding. Molecular Cell, 1999, 4, 153-166.	9.4	471
403	Phosphoinositide Binding Domains. Cell, 1999, 97, 817-820.	27.3	129
404	Mouse Phosphoinositide 3-Kinase p110Î± Gene: Cloning, Structural Organization, and Localization to Chromosome 3 Band B. Biochemical and Biophysical Research Communications, 1999, 262, 438-442.	2.2	6
405	PI 3-KINASE KNOCKOUT MICE: ROLE OF p85Î± IN B CELL DEVELOPMENT AND PROLIFERATION. Biochemical Society Transactions, 1999, 27, A73-A73.	3.4	0
406	The Use of Peptide Library for the Determination of Kinase Peptide Substrates. , 1998, 87, 87-98.		40
407	Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO Journal, 1998, 17, 1961-1972.	7.6	419
408	A flattened face for membranes. Nature Structural and Molecular Biology, 1998, 5, 843-845.	7.8	7
409	Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins. Oncogene, 1998, 16, 891-901.	5.8	59
410	Analysis of an Activator:Coactivator Complex Reveals an Essential Role for Secondary Structure in Transcriptional Activation. Molecular Cell, 1998, 2, 353-359.	9.4	156
411	Extracellular HIV-1 Tat Protein Induces a Rapid and Selective Activation of Protein Kinase C (PKC)-Î±, -Ïµ, and -Î¶ Isoforms in PC12 Cells. Biochemical and Biophysical Research Communications, 1998, 242, 332-337.	2.2	35
412	PHOSPHOINOSITIDE KINASES. Annual Review of Biochemistry, 1998, 67, 481-507.	10.9	1,376
413	SRPK2: A Differentially Expressed SR Protein-specific Kinase Involved in Mediating the Interaction and Localization of Pre-mRNA Splicing Factors in Mammalian Cells. Journal of Cell Biology, 1998, 140, 737-750.	5.1	277
414	Type I Phosphatidylinositol-4-phosphate 5-Kinases Synthesize the Novel Lipids Phosphatidylinositol 3,5-Bisphosphate and Phosphatidylinositol 5-Phosphate. Journal of Biological Chemistry, 1998, 273, 18040-18046.	3.4	123

#	Article	IF	Citations
415	Differential Signaling by the Epidermal Growth Factor-like Growth Factors Neuregulin-1 and Neuregulin-2. Journal of Biological Chemistry, 1998, 273, 26954-26961.	3.4	77
416	Regulation of GRP1-catalyzed ADP Ribosylation Factor Guanine Nucleotide Exchange by Phosphatidylinositol 3,4,5-Trisphosphate. Journal of Biological Chemistry, 1998, 273, 1859-1862.	3.4	150
417	Association of Protein Kinase CÎ¼ with Type II Phosphatidylinositol 4-Kinase and Type I Phosphatidylinositol-4-phosphate 5-Kinase. Journal of Biological Chemistry, 1998, 273, 23126-23133.	3.4	91
418	Phosphoinositide 3-Kinase Regulates Phospholipase CÎ³-mediated Calcium Signaling. Journal of Biological Chemistry, 1998, 273, 23750-23757.	3.4	209
419	Activation of P2Y2 Receptors by UTP and ATP Stimulates Mitogen-activated Kinase Activity through a Pathway That Involves Related Adhesion Focal Tyrosine Kinase and Protein Kinase C. Journal of Biological Chemistry, 1998, 273, 2653-2660.	3.4	167
420	Corequirement of Specific Phosphoinositides and Small GTP-binding Protein Cdc42 in Inducing Actin Assembly in Xenopus Egg Extracts. Journal of Cell Biology, 1998, 140, 1125-1136.	5.1	219
421	Characterization of a Rac1- and RhoGDI-Associated Lipid Kinase Signaling Complex. Molecular and Cellular Biology, 1998, 18, 762-770.	2.4	164
422	Cloning and Characterization of a Wortmannin-sensitive Human Phosphatidylinositol 4-Kinase. Journal of Biological Chemistry, 1997, 272, 4384-4390.	3.4	150
423	The Cbl Phosphotyrosine-binding Domain Selects a D(N/D)XpY Motif and Binds to the Tyr292Negative Regulatory Phosphorylation Site of ZAP-70. Journal of Biological Chemistry, 1997, 272, 33140-33144.	3.4	193
424	The Lipid Products of Phosphoinositide 3-Kinase Increase Cell Motility through Protein Kinase C. Journal of Biological Chemistry, 1997, 272, 6465-6470.	3.4	126
425	Conditional Inhibition of the Mitogen-activated Protein Kinase Cascade by Wortmannin. Journal of Biological Chemistry, 1997, 272, 27665-27670.	3.4	184
426	A Comparative Analysis of the Phosphoinositide Binding Specificity of Pleckstrin Homology Domains. Journal of Biological Chemistry, 1997, 272, 22059-22066.	3.4	420
427	The SH3 Domain of Amphiphysin Binds the Proline-rich Domain of Dynamin at a Single Site That Defines a New SH3 Binding Consensus Sequence. Journal of Biological Chemistry, 1997, 272, 13419-13425.	3.4	236
428	Determination of the Specific Substrate Sequence Motifs of Protein Kinase C Isozymes. Journal of Biological Chemistry, 1997, 272, 952-960.	3.4	521
429	Interleukin 3-dependent survival by the Akt protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11345-11350.	7.4	339
430	Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3016-3021.	7.4	166
431	Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate. Science, 1997, 275, 665-668.	19.6	1,447
432	Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase. Science, 1997, 276, 1848-1850.	19.6	399

#	Article	IF	Citations
433	Sequence-Specific and Phosphorylation-Dependent Proline Isomerization: A Potential Mitotic Regulatory Mechanism. Science, 1997, 278, 1957-1960.	19.6	769
434	The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity. Cell, 1997, 91, 961-971.	27.3	1,528
435	PI3K: Downstream AKTion Blocks Apoptosis. Cell, 1997, 88, 435-437.	27.3	1,586
436	A Bad kinase makes good. Nature, 1997, 390, 116-117.	35.3	183
437	High-affinity binding of the Drosophila Numb phosphotyrosine-binding domain to peptides containing a Gly-Pro-(p)Tyr motif. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7204-7209.	7.4	70
438	Subcellular Locations of Phosphatidylinositol 4-Kinase Isoforms. Journal of Biological Chemistry, 1997, 272, 13236-13241.	3.4	164
439	A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature, 1997, 390, 192-196.	35.3	454
440	Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature, 1997, 387, 673-676.	35.3	1,292
441	Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO Journal, 1997, 16, 3877-3888.	7.6	265
442	Regulatory interactions in the recognition of endocytic sorting signals by AP-2 complexes. EMBO Journal, 1997, 16, 2240-2250.	7.6	198
443	4 Specificity in protein-tyrosine kinase signaling. Advances in Second Messenger and Phosphoprotein Research, 1997, 31, 41-48.	0.0	15
444	Association of phosphatidylinositol 3-kinase, via the SH2 domains of p85, with focal adhesion kinase in polyoma middle t-transformed fibroblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1311, 45-52.	4.0	38
445	Structural Organization and Alternative Splicing of the Murine Phosphoinositide 3-Kinase p85Î± Gene. Genomics, 1996, 37, 113-121.	2.9	119
446	Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2. Cell, 1996, 87, 1181-1190.	27.3	741
447	Phosphoinositide kinases. Current Opinion in Cell Biology, 1996, 8, 153-158.	5.4	580
448	p120 Is a Major Substrate of Tyrosine Phosphorylation upon B Cell Antigen Receptor Stimulation and Interacts in Vivo with Fyn and Syk Tyrosine Kinases, Grb2 and Shc Adaptors, and the p85 Subunit of Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 1996, 271, 3187-3194.	3.4	161
449	Specificity of LIM Domain Interactions with Receptor Tyrosine Kinases. Journal of Biological Chemistry, 1996, 271, 15934-15941.	3.4	91
450	Binding Specificity and Mutational Analysis of the Phosphotyrosine Binding Domain of the Brain-specific Adaptor Protein ShcC. Journal of Biological Chemistry, 1996, 271, 11787-11791.	3.4	18

#	Article	IF	Citations
451	The Inositol 5â€²-Phosphatase SHIP Binds to Immunoreceptor Signaling Motifs and Responds to High Affinity IgE Receptor Aggregation. Journal of Biological Chemistry, 1996, 271, 29271-29278.	3.4	168
452	Regulation of the Lck SH2 Domain by Tyrosine Phosphorylation. Journal of Biological Chemistry, 1996, 271, 24880-24884.	3.4	75
453	Extracellular Human Immunodeficiency Virus Type-1 Tat Protein Activates Phosphatidylinositol 3-Kinase in PC12 Neuronal Cells. Journal of Biological Chemistry, 1996, 271, 22961-22964.	3.4	65
454	p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells. Journal of Biological Chemistry, 1996, 271, 563-567.	3.4	129
455	D3 Phosphoinositides and Outside-in integrin Signaling by Glycoprotein IIb-IIIa Mediate Platelet Actin Assembly and Filopodial Extension Induced by Phorbol 12-Myristate 13-Acetate. Journal of Biological Chemistry, 1996, 271, 32986-32993.	3.4	114
456	PI 3-Kinase and Receptor-Linked Signal Transduction. , 1996, , 125-175.		8
457	The Structural Basis for Specificity in Protein-Tyrosine Kinase Signaling. , 1996, , 5-16.		0
458	[35] SH2 domain specificity determination using oriented phosphopeptide library. Methods in Enzymology, 1995, 254, 523-535.	1.7	34
459	Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends in Biochemical Sciences, 1995, 20, 470-475.	7.3	354
460	Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 1995, 373, 536-539.	35.3	939
461	Type 2 phosphatidylinositol 4-kinase is recruited to CD4 in response to CD4 cross-linking. BBA - Proteins and Proteomics, 1995, 1248, 129-134.	2.0	15
462	The SH3 Domain-binding T Cell Tyrosyl Phosphoprotein p120. Journal of Biological Chemistry, 1995, 270, 19141-19150.	3.4	178
463	A Single Point Mutation Switches the Specificity of Group III Src Homology (SH) 2 Domains to That of Group I SH2 Domains. Journal of Biological Chemistry, 1995, 270, 26029-26032.	3.4	73
464	The Phosphotyrosine Interaction Domain of SHC Recognizes Tyrosine-phosphorylated NPXY Motif. Journal of Biological Chemistry, 1995, 270, 14863-14866.	3.4	166
465	Rho Family GTPases Bind to Phosphoinositide Kinases. Journal of Biological Chemistry, 1995, 270, 17656-17659.	3.4	446
466	T Cell Activation-dependent Association between the p85 Subunit of the Phosphatidylinositol 3-Kinase and Grb2/Phospholipase C-Î³1-binding Phosphotyrosyl Protein pp36/38. Journal of Biological Chemistry, 1995, 270, 20177-20182.	3.4	80
467	Phosphorylation of the Platelet p47 Phosphoprotein Is Mediated by the Lipid Products of Phosphoinositide 3-Kinase. Journal of Biological Chemistry, 1995, 270, 29525-29531.	3.4	70
468	Phosphatidylinositol 4,5-Bisphosphate Synthesis Is Required for Activation of Phospholipase D in U937 Cells. Journal of Biological Chemistry, 1995, 270, 5130-5135.	3.4	114

#	Article	IF	Citations
469	Phosphoinositide 3-Kinase Inhibition Spares Actin Assembly in Activating Platelets but Reverses Platelet Aggregation. Journal of Biological Chemistry, 1995, 270, 11358-11366.	3.4	204
470	Phosphoinositide 3-Kinase Binds Constitutively to Î±/Î²-Tubulin and Binds to Î³-Tubulin in Response to Insulin. Journal of Biological Chemistry, 1995, 270, 25985-25991.	3.4	101
471	Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3. Journal of Biological Chemistry, 1995, 270, 7111-7116.	3.4	131
472	Identification of efficient pentapeptide substrates for the tyrosine kinase pp60c-src. Journal of Medicinal Chemistry, 1995, 38, 4276-4283.	6.5	32
473	Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell, 1995, 83, 821-830.	27.3	315
474	Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 1995, 80, 729-738.	27.3	954
475	Signal transduction and membrane traffic: The PITP/phosphoinositide connection. Cell, 1995, 81, 659-662.	27.3	281
476	Specificity in recognition of phosphopeptides by src-homology 2 domains. Journal of Cell Science, 1994, 1994, 121-126.	2.0	61
477	SH2 domain specificity and activity modified by a single residue. Nature, 1994, 369, 502-505.	35.3	200
478	Use of an oriented peptide library to determine the optimal substrates of protein kinases. Current Biology, 1994, 4, 973-982.	3.9	629
479	A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell, 1994, 78, 5-8.	27.3	603
480	Blockade of ATP binding site of P2 purinoceptors in rat parotid acinar cells by isothiocyanate compounds. Biochemical Pharmacology, 1993, 45, 1936-1940.	4.5	47
481	Role of Phosphatidylinositol 3-Kinase in Growth Factor and Oncogene Signaling. , 1993, , 149-165.		0
482	Phosphatidylinositol 3-kinase: A Novel Signal Transduction Pathway?. , 1992, , 175-194.		0
483	Oncogenes and signal transduction. Cell, 1991, 64, 281-302.	27.3	2,874
484	Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods in Enzymology, 1991, 198, 78-87.	1.7	142
485	Mutations in the Juxtamembrane Region of the Insulin Receptor Impair Activation of Phosphatidylinositol 3-Kinase by Insulin. Molecular Endocrinology, 1991, 5, 769-777.	3.4	49
486	1,25(OH)2D3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. Journal of Nutritional Biochemistry, 1990, 1, 81-87.	4.2	57

#	Article	IF	Citations
487	Phosphoinositide kinases. Biochemistry, 1990, 29, 11147-11156.	2.6	353
488	Phosphoinositide metabolism and the control of cell proliferation. Biochimica Et Biophysica Acta: Reviews on Cancer, 1989, 948, 327-344.	7.5	76
489	The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase. Nature, 1989, 342, 699-702.	35.3	354
490	PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell, 1989, 57, 167-175.	27.3	951
491	Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature, 1988, 332, 644-646.	35.3	1,023
492	Location of sites in human lipocortin I that are phosphorylated by protein tyrosine kinases and protein kinases A and C. Biochemistry, 1988, 27, 3682-3690.	2.6	101
493	Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell, 1987, 50, 1021-1029.	27.3	709
494	Kinetic analysis of guanosine 5'-O-(3-thiotriphosphate) effects on phosphatidylinositol turnover in NRK cell homogenates. Biochemistry, 1987, 26, 612-622.	2.6	26
495	Bovine brain contains two types of phosphatidylinositol kinase. Biochemistry, 1987, 26, 6845-6852.	2.6	137
496	Ion transport systems sequenced. Trends in Neurosciences, 1986, 9, 1-3.	8.7	46
497	Structural Aspects of the Red Cell Anion Exchange Protein. Annual Review of Biochemistry, 1986, 55, 511-538.	10.9	164
498	Protein kinase C of human erythrocytes phosphorylates bands 4.1 and 4.9. Biochimica Et Biophysica Acta - Molecular Cell Research, 1986, 887, 142-149.	4.0	29
499	Comparison of the Na+ Pump and the Ouabain-Resistant K+ Transport System with Other Metal Ion Transport ATPases. , 1986, , 249-259.		0
500	Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature, 1985, 315, 239-242.	35.3	850
501	Delta endotoxin inhibits Rb+ uptake, lowers cytoplasmic pH and inhibits a K+-ATPase inManduca sexta CHE cells. Journal of Membrane Biology, 1985, 85, 199-204.	2.2	30
502	Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell, 1985, 40, 583-590.	27.3	286
503	Na+ and Ca2+ Fluxes and Differentiation of Transformed Cells. , 1985, , 173-178.		0
504	Characterization of monovalent ion transport systems in an insect cell line (Manduca sexta) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td	4.1	18

#	Article	IF	Citations
505	The plasma membrane (Mg2+)-dependent adenosine triphosphatase from the human erythrocyte is not an ion pump. Journal of Membrane Biology, 1984, 80, 185-190.	2.2	21
506	Ionic regulation of MEL cell commitment. Journal of Cellular Biochemistry, 1983, 21, 1-8.	2.6	9
507	Conformational Changes of Na,K-ATPase Necessary for Transport. Current Topics in Membranes and Transport, 1983, , 315-322.	0.0	13
508	The Structure and Function of Band 3. , 1983, , 41-87.		32
509	Role of mitochondrial membrane potential in the regulation of murine erythroleukemia cell differentiation. Cell, 1982, 28, 855-863.	27.3	79
510	Mechanism of anion exchange across the red cell membrane by band 3: interactions between stilbenedisulfonate and NAP-taurine binding sites. Biochemistry, 1981, 20, 5695-5701.	2.6	55
511	Interactions between transport inhibitors at the anion binding sites of the band 3 dimer. Biochemistry, 1981, 20, 5095-5105.	2.6	79
512	Structure and Mechanism of the (Na,K)-ATPase. Current Topics in Bioenergetics, 1981, 11, 201-237.	0.0	299
513	Structural changes in (Na+ + K+)-ATPase accompanying detergent inactivation. Biochimica Et Biophysica Acta - Biomembranes, 1980, 599, 436-447.	2.7	12
514	Location of the stilbenedisulfonate binding site of the human erythrocyte anion-exchange system by resonance energy transfer. Biochemistry, 1979, 18, 4505-4516.	2.6	132
515	Vanadate inhibits the red cell (Na+, K+) ATPase from the cytoplasmic side. Nature, 1978, 272, 552-554.	35.3	382
516	Norepinephrine complexes and reduced vanadium(V) to reverse vanadate inhibition of the (sodium,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	14.1	105
517	Reaction of (sodium(1+)-potassium(1+) ion)-activated ATPase with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole: evidence for an essential tyrosine at the active site. Biochemistry, 1978, 17, 418-425.	2.6	89
518	Isolation of a potent (Na -K) stimulated ATPase inhibitor from striated muscle. Biochemistry, 1977, 16, 4572-4578.	2.6	266
519	A slow interconversion between active and inactive states of the (sodium + potassium ion)-dependent ATPase. Biochemistry, 1976, 15, 5280-5287.	2.6	50
520	Characterization of sulfhydryl groups on chloroplast coupling factor 1 exposed by heat activation. Biochemistry, 1976, 15, 9-14.	2.6	43
521	Investigation of quercetin binding sites on chloroplast coupling factor. Biochemistry, 1976, 15, 1-8.	2.6	91
522	Characterization of nucleotide binding sites on chloroplast coupling factor 1. Biochemistry, 1975, 14, 2968-2975.	2.6	135

#	Article	IF	Citations
523	Fluorescence energy transfer between ligand binding sites on chloroplast coupling factor 1. Biochemistry, 1975, 14, 2976-2981.	2.6	84
524	Activation of beef heart mitochondrial adenosine triphosphatase by 2,4-dinitrophenol. Biochemistry, 1973, 12, 4900-4904.	2.6	72
525	NRF2 Rewires Cellular Metabolism to Support the Antioxidant Response. , 0, , .		30